Company: BDRX
Filing Date: 2025-11-17
Form Type: F-1
Source: 0001214659-25-016821
Chunk: 33

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-11-17
Form: F-1
Chunk 33
---
 upon our current plans and assumptions regarding industry and general economic
conditions, our future revenues and expenditures.

As of the date of this prospectus,
we cannot predict with certainty all of the particular uses for the net proceeds to be received upon completion of this offering, or the
amount we will actually spend on the uses set forth above. The amounts and timing of our actual use of net proceeds will vary depending
on numerous factors, including the relative success and cost of our research and development programs, our ability to gain access to additional
financing, and other factors described under “Risk Factors” in this prospectus and in our Annual Report on Form 20-F for the
year ended December 31, 2024. As a result, our management will have broad discretion in the application of the net proceeds, and investors
will be relying on our management’s judgment regarding the application of the net proceeds of this offering.

Pending the application of
the net proceeds as described above, we will hold the net proceeds from this offering in short-term, interest-bearing, securities.

| 21 |

<div align='center'>DIVIDEND POLICY</div>

Since inception, we have never
declared or paid any cash dividends on our Ordinary Shares and do not anticipate paying any cash dividends on our Ordinary Shares or the
Depositary Shares in the foreseeable future. We intend to retain all available funds and any future earnings to fund the development and
expansion of our business. As a result, investors in the Ordinary Shares and Depositary Shares will benefit in the foreseeable future
only if the Ordinary Shares and Depositary Shares appreciate in value.

Any determination to pay dividends
in the future would be at the discretion of our Board of Directors and will depend upon our results of operations, cash requirements,
financial condition, contractual restrictions, and any future debt agreements and is subject to compliance with applicable laws, including
the Companies Act 2006 (as amended from time to time) of the United Kingdom, or the Companies Act, which requires English companies to
have profits available for distribution equal to or greater than the amount of the proposed dividend.

| 22 |

<div align='center'>CAPITALIZATION</div>

The following table sets forth
our capitalization as of June 30, 2025:

| · | on an actual basis; and |

| · | on an as-adjusted basis to give effect to the sale by us of 3,377,110 Units in this offering at an assumed                                   
 combined public offering price of